USOR 24320 - STAR: Ph3 multicenter study of taletrectinib in patients with ROS1-FUSION with NSCLC

A PHASE 3 MULTICENTER DOUBLE-BLIND RANDOMIZED STUDY OF TALETRECTINIB VERSUS PLACEBO IN PATIENTS WITH ROS1-FUSION POSITIVE STAGE IB-IIIA NON-SMALL CELL LUNG CANCER WHO HAVE UNDERGONE COMPLETE TUMOR RESECTION

Disease Types: STAR: Selected Trials Available for Accelerated Four Week Rollout

Available at: Arlington Heights, Chicago Resurrection, Niles